Angiogenesis Research: Guidelines for Translation to Clinical Application
Angiogenesis Research: Guidelines for Translation to Clinical Application
复制标题
DOI：
10.1055/s-0037-1616197
复制
发表时间：
2001-07
影响因子：
6.7
通讯作者：
J. Folkman;T. Browder;J. Palmblad
中科院分区：
文献类型：
--
作者：
J. Folkman;T. Browder;J. Palmblad
摘要血管生成研究正在转化为临床研究。某些指导方针可能会促进这一努力。肿瘤对内皮细胞的募集是血管生成的早期事件，这是一个在遗传和表观遗传水平上受到调控的过程。微血管内皮细胞已成为肿瘤治疗的第二个重要靶点。血管生成抑制剂有“直接”或“间接”两种，它们的最佳剂量取决于与传统化疗不同的逻辑。相反，化疗的抗血管生成计划可以绕过耐药性。像所有实体肿瘤一样，血液系统的恶性肿瘤依赖于血管生成。此外，血管生成受到来自造血系统和止血系统的蛋白质和细胞的调节。血管生成抑制剂的临床测试强调了对肿瘤血管生成活性的替代标记物的需求。微血管密度作为转移风险的预后指标很有价值，但不能决定血管生成抑制剂的疗效。未来，血管生成抑制剂可能会被添加到化疗或放射治疗中，或添加到其他方法中。此外，血管生成抑制剂的组合也可以一起使用。
Summary Angiogenesis research is being translated to the clinic. Certain guidelines may facilitate this effort. Recruitment of endothelial cells by a tumor is an early event in angiogenesis, a process regulated at genetic and epigenetic levels. The microvascular endothelial cell has become an important second target in cancer therapy. Angiogenesis inhibitors are either “direct” or “indirect” and their optimal dosing depends on a different logic than conventional chemotherapy. Conversely, antiangiogenic scheduling of chemotherapy can by-pass drug resistance. Like all solid tumors, hematologic malignancies are angiogenesis-dependent. Further, angiogenesis is modulated by proteins and cells from the hematopoietic and hemostatic systems. Clinical testing of angiogenesis inhibitors has accentuated the need for surrogate markers of tumor angiogenesis activity. Microvessel density, so valuable as a prognostic indicator of metastatic risk, cannot determine efficacy of an angiogenesis inhibitor. In the future, angiogenesis inhibitors may be added to chemotherapy or to radiotherapy, or to other modalities. Also, combinations of angiogenesis inhibitors may be administered together.